A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis
Status:
Terminated
Trial end date:
2021-09-03
Target enrollment:
Participant gender:
Summary
This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 90 day, safety,
efficacy, and systemic exposure study followed by a 90 day open-label extension of
trifarotene cream in adults and adolescents with autosomal recessive ichthyosis with lamellar
scale.